2022
Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting
Haque LY, Butner JL, Shi JM, Henry S, Deng Y, Ciarleglio MM, Madden LM, Tetrault JM. Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting. Journal Of Addiction Medicine 2022, 16: 333-339. PMID: 34483278, PMCID: PMC9033626, DOI: 10.1097/adm.0000000000000910.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionUrine toxicology resultsDirect acting antiviralsViral load testingSubstance use disordersAddiction treatment programsHCV reinfectionActing antiviralsToxicology resultsUse disordersDirect acting antiviral therapyTreatment programReal-world clinical settingHCV reinfection ratesActing antiviral (DAA) therapyC virus infectionHepatitis C infectionMedical service useCohort of patientsPrimary medical careSubstance use statusAddiction treatment settingsQuality improvement initiativesHCV cureC infectionChapter 9 Addiction management in the outpatient setting
Shi J, Slocum B, Tetrault J, Yanagisawa K. Chapter 9 Addiction management in the outpatient setting. 2022, 169-187. DOI: 10.1016/b978-0-323-79016-1.00008-8.Peer-Reviewed Original ResearchOpioid use disorderNonmedical opioid useOpioid useUntreated opioid use disorderPain management strategiesCurrent treatment optionsOpioid overdose crisisPostoperative painOutpatient settingTreatment optionsRisk factorsGeneral practitionersHigh riskEarly deathUse disordersAddiction specialistsCurrent opioid overdose crisisMedical providersBrain physiologyInfectious diseasesAddiction managementOverdose crisisAffected individualsDisordersThoughtful approach
2021
Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants
Thompson SL, Gianessi CA, O'Malley SS, Cavallo DA, Shi JM, Tetrault JM, DeMartini KS, Gueorguieva R, Pittman B, Krystal JH, Taylor JR, Krishnan-Sarin S. Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants. Frontiers In Psychiatry 2021, 12: 709559. PMID: 34531767, PMCID: PMC8438169, DOI: 10.3389/fpsyt.2021.709559.Peer-Reviewed Original ResearchNMDA receptorsSrc/FynAlcohol consumptionEffect of saracatinibVehicle 2 hChronic alcohol useDays of treatmentDSM-IV criteriaMore effective treatmentsNumber of drinksGlutamatergic systemAdditional drinkAlcohol drinkingAdditional dosesEthanol exposureEffective treatmentNR2B subunitAlcohol abuseHuman studiesPriming drinkAlcohol cravingSaracatinibDrinking paradigmNovel pharmacotherapeuticsHuman participants
2019
Galantamine to reduce relapse after agonist taper for individuals with opioid use disorder
Sofuoglu M, Shi JM, Carroll KM. Galantamine to reduce relapse after agonist taper for individuals with opioid use disorder. Drug And Alcohol Dependence 2019, 203: 98. PMID: 31421476, DOI: 10.1016/j.drugalcdep.2019.05.013.Peer-Reviewed Original ResearchThe Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving
de Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.Peer-Reviewed Original ResearchConceptsKappa-opioid receptorsAlcohol use disorderOpioid receptorsUse disordersNonselective opioid receptor antagonistModest clinical effectsEfficacy of naltrexoneOpioid receptor antagonistDSM-IV criteriaPositron emission tomographyAlcohol Urge QuestionnaireNaltrexone initiationNaltrexone therapyClinical effectsReceptor antagonistTherapeutic effectCingulate cortexDrinking paradigmHeavy drinkersBilateral insulaNaltrexoneAlcohol dependenceBrain regionsEmission tomographyPrefrontal cortexRandomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for use in Office-Based Buprenorphine Maintenance
Shi JM, Henry SP, Dwy SL, Orazietti SA, Carroll KM. Randomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for use in Office-Based Buprenorphine Maintenance. Substance Abuse 2019, 40: 132-135. PMID: 30714880, PMCID: PMC6874094, DOI: 10.1080/08897077.2019.1569192.Peer-Reviewed Original ResearchConceptsOffice-based buprenorphineOpioid use disorderBuprenorphine treatmentWeb-based interventionBuprenorphine maintenancePilot trialUse disordersBehavioral careCurrent opioid use disorderOffice-based buprenorphine treatmentUrine toxicology screenSpecific patient populationsDays of treatmentDSM-5 criteriaCognitive behavioral therapyInitial pilot testingToxicology screenPatient populationTwelve-weekEffective treatmentBuprenorphineDrug useSmall sample sizeTrialsPromising findings
2018
Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users
Roberts W, Shi JM, Tetrault JM, McKee SA. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users. Journal Of Addiction Medicine 2018, 12: 227-233. PMID: 29438157, PMCID: PMC5970035, DOI: 10.1097/adm.0000000000000392.Peer-Reviewed Original ResearchConceptsLow-dose naltrexoneTobacco usersTreatment outcomesPlacebo-controlled human laboratory studySmoking cessation treatmentEffects of vareniclineCigarettes ad libitumHuman laboratory studiesSubjective drug effectsVarenicline monotherapyCessation medicationsMedication therapyCessation treatmentMedication armTobacco useVareniclineLow doseSmoking relapseSmokingDrug effectsSmoking outcomesSmoking behaviorNaltrexoneCarbon monoxide levelsHeavy drinkersPilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior
Verplaetse TL, Weinberger AH, Ashare RL, Pittman BP, Shi JM, Tetrault JM, Lavery M, McKee SA. Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior. Journal Of Psychopharmacology 2018, 32: 1003-1009. PMID: 29692206, PMCID: PMC6258014, DOI: 10.1177/0269881118767647.Peer-Reviewed Original ResearchConceptsEffects of carvedilolSmoking lapse behaviorAdrenergic antagonistsTobacco cravingSmoking outcomesPhysiologic reactivitySystolic blood pressureNumber of cigarettesNicotine-motivated behaviors× time effectSelf-administration periodEffects of α1Human laboratory modelNicotine-deprived smokersPlacebo groupBlood pressureAdrenergic antagonismMedication conditionClinical indicationsNoradrenergic systemSubsequent smokingHeart rateProperties of drugsSmokingCarvedilolAn investigation of an open‐access model for scaling up methadone maintenance treatment
Madden LM, Farnum SO, Eggert KF, Quanbeck AR, Freeman RM, Ball SA, Schottenfeld RS, Shi JM, Savage ME, Barry DT. An investigation of an open‐access model for scaling up methadone maintenance treatment. Addiction 2018, 113: 1450-1458. PMID: 29453891, DOI: 10.1111/add.14198.Peer-Reviewed Original ResearchConceptsNon-medical opioid useOpioid use disorderMethadone maintenance treatmentOpioid useMaintenance treatmentTreatment accessUse disordersTreatment modelMethadone maintenance treatment centersMaintenance treatment centersDeleterious effectsMethadone treatmentPatient mortalityTreatment optionsTreatment outcomesTreatment centersProspective patientsRate of retentionPatient censusRapid enrollmentAddiction treatmentApparent deleterious effectsTreatmentMortalityProgrammatic outcomesGalantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial.
Carroll KM, Nich C, DeVito EE, Shi JM, Sofuoglu M. Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2018, 79: 17m11669. PMID: 29286595, PMCID: PMC5866530, DOI: 10.4088/jcp.17m11669.Peer-Reviewed Original ResearchConceptsComputerized cognitive behavioral therapyStandard methadone treatmentCocaine use outcomesBenefits of galantamineMethadone treatmentCognitive behavioral therapyCognitive functionUse outcomesCommunity-based methadone maintenance programCocaine useStandard methadone maintenance treatmentBehavioral therapyUrine toxicology screenMethadone maintenance treatmentMethadone maintenance programCocaine treatment outcomesNicotinic acetylcholine receptorsCognitive functioningCocaine use disorderMethadone dosingSecondary outcomesToxicology screenMaintenance treatmentClinical trialsMedication administration
2017
Effect of doxazosin on stress reactivity and the ability to resist smoking
Verplaetse TL, Weinberger AH, Oberleitner LM, Smith KM, Pittman BP, Shi JM, Tetrault JM, Lavery ME, Picciotto MR, McKee SA. Effect of doxazosin on stress reactivity and the ability to resist smoking. Journal Of Psychopharmacology 2017, 31: 830-840. PMID: 28440105, PMCID: PMC5823502, DOI: 10.1177/0269881117699603.Peer-Reviewed Original ResearchConceptsTobacco cravingCortisol levelsSubsequent ad libitum smokingEffects of doxazosinAd libitum smokingNumber of cigarettesNicotine-motivated behaviorsSmoking lapse behaviorΑ1-adrenergic antagonistNicotine-deprived smokersTitration periodPreclinical findingsSmoking cessationNoradrenergic systemTreatment strategiesDoxazosinSmoking behaviorSmokingHuman laboratoryPhysiologic reactivityPilot studyStress reactivityEffects of stressCigarettesStress imageryOnsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal Of Substance Use And Addiction Treatment 2017, 75: 49-53. PMID: 28237054, DOI: 10.1016/j.jsat.2016.12.014.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsOpioid treatment programsPercent of patientsHCV treatmentHCV infectionActing antiviralsTreatment outcomesTreatment programOral HCV treatmentSustained virologic responseHCV treatment outcomesRoutine clinical careOngoing drug useVirologic responseRetrospective studyClinical careGeneral populationPatientsDrug useTreatmentOutcomesAntiviralsInfectionPercentPWID
2016
Effect of Varenicline Combined with High‐Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings
Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Varenicline Combined with High‐Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings. Alcohol Clinical And Experimental Research 2016, 40: 1567-1576. PMID: 27246567, PMCID: PMC4930423, DOI: 10.1111/acer.13110.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol-Related DisordersAlcoholic IntoxicationAssociation LearningBlood PressureCravingDose-Response Relationship, DrugDouble-Blind MethodEthanolExecutive FunctionFemaleHeart RateHumansMaleMemory, Short-TermNicotinic AgonistsPsychological TestsPsychomotor PerformanceVareniclineYoung AdultConceptsPerceptual-motor functionAlcohol use disorderExecutive cognitive functionCognitive functionDose of alcoholSubjective reactivitySubjective intoxicationHigh-dose alcoholNonalcoholic control beverageAlcohol-motivated behaviorsUse disordersEffects of vareniclineAssociative learningAversive eventsLaboratory paradigmDiastolic blood pressureAlcohol cravingControl beverageMotor responsePhysiologic reactivityAlcohol-related increasesLaboratory sessionsMotor functionBlood pressurePreliminary investigationEffect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders
Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders. Journal Of Addiction Medicine 2016, 10: 166-173. PMID: 27159341, PMCID: PMC4880525, DOI: 10.1097/adm.0000000000000208.Peer-Reviewed Original ResearchConceptsAlcohol use disorderEffects of vareniclineAlcohol consumptionUse disordersVarenicline doseD dosePlasma levelsDose of vareniclineDoses of vareniclineFrequency of insomniaPlacebo-controlled investigationHigher plasma levelsDose of alcoholAlcohol Self-AdministrationSelf-administration periodMedication pretreatmentAdverse eventsEdition criteriaVareniclineLow doseSide effectsAlcohol cravingMeeting criteriaPhysiologic responsesAlcohol-related outcomesA randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence
Carroll KM, Nich C, Petry NM, Eagan DA, Shi JM, Ball SA. A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug And Alcohol Dependence 2016, 160: 135-142. PMID: 26817621, PMCID: PMC4767616, DOI: 10.1016/j.drugalcdep.2015.12.036.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyCocaine outcomesCocaine dependenceCombination of CMDouble-blind clinical trialBehavioral therapyCommunity-based outpatient clinicsUrine sample testingBlind clinical trialSustained treatment effectContingency managementDSM-IV criteriaRandomized factorial trialCurrent cocaine dependenceWeekly individual sessionsCocaine use disorderSecondary outcomesPrimary outcomeYear followOutpatient clinicAddition of disulfiramClinical trialsUse disordersCBT treatmentFactorial trial
2015
N‐Methyl‐d‐Aspartate Receptor Antagonism has Differential Effects on Alcohol Craving and Drinking in Heavy Drinkers
Krishnan‐Sarin S, O'Malley SS, Franco N, Cavallo DA, Morean M, Shi J, Pittman B, Krystal JH. N‐Methyl‐d‐Aspartate Receptor Antagonism has Differential Effects on Alcohol Craving and Drinking in Heavy Drinkers. Alcohol Clinical And Experimental Research 2015, 39: 300-307. PMID: 25664775, PMCID: PMC4331214, DOI: 10.1111/acer.12619.Peer-Reviewed Original ResearchConceptsAlcohol drinkingFamily historyHeavy drinkersAlcohol cravingN-methyl-D-aspartate receptor antagonistN-methyl-D-aspartate receptor antagonismAlcohol cue-induced cravingEffects of FHHigher baseline levelsPresence of impulsivityAlcohol use disorderCue-induced cravingAlcohol-induced stimulationReceptor antagonismReceptor antagonistPriming doseNMDA receptorsUse disordersMemantineBaseline levelsModulatory influencePotential efficacyAlcohol accessDrinkersEighth day
2014
Ethyl Glucuronide and Ethyl Sulfate Assays in Clinical Trials, Interpretation, and Limitations: Results of a Dose Ranging Alcohol Challenge Study and 2 Clinical Trials
Jatlow PI, Agro A, Wu R, Nadim H, Toll BA, Ralevski E, Nogueira C, Shi J, Dziura JD, Petrakis IL, O'Malley SS. Ethyl Glucuronide and Ethyl Sulfate Assays in Clinical Trials, Interpretation, and Limitations: Results of a Dose Ranging Alcohol Challenge Study and 2 Clinical Trials. Alcohol Clinical And Experimental Research 2014, 38: 2056-2065. PMID: 24773137, PMCID: PMC4107122, DOI: 10.1111/acer.12407.Peer-Reviewed Original ResearchConceptsEtG/EtSClinical trialsEthyl glucuronideRecent alcohol consumptionEvaluation of outcomesAlcohol challenge studyBlood concentrationsAlcohol dosesLow doseLight drinkingAlcohol consumptionChallenge studiesCutoff concentrationDrinking historyTimed intervalsAbstinenceTrialsHeavy consumptionDrinkingDoseGlucuronideObjective measuresHoursCutoffEtG
2013
A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self‐administration
Udo T, Harrison EL, Shi J, Tetrault J, McKee SA. A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self‐administration. American Journal On Addictions 2013, 22: 590-597. PMID: 24131167, PMCID: PMC3934424, DOI: 10.1111/j.1521-0391.2013.12014.x.Peer-Reviewed Original ResearchConceptsSelf-administration periodNicotine nasal sprayHeavy drinking smokersNasal sprayNicotine patchAlcohol responsesPriming drinkSerum nicotine levelsPlacebo-controlled studyNicotine replacement therapySubjective alcohol responsesPositive subjective responsesNumber of drinksPlacebo administrationReplacement therapyPriming doseSmoking relapseAlcohol consumptionPlacebo conditionPatch applicationNicotine levelsClinical settingPilot studySmokersSubjective responses
2012
Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: A randomized placebo-controlled trial
Carroll KM, Nich C, Shi JM, Eagan D, Ball SA. Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: A randomized placebo-controlled trial. Drug And Alcohol Dependence 2012, 126: 224-231. PMID: 22695473, PMCID: PMC3461119, DOI: 10.1016/j.drugalcdep.2012.05.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol DeterrentsAlcohol DrinkingCocaine-Related DisordersCounselingDemographyDiagnostic and Statistical Manual of Mental DisordersDisulfiramDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMethadoneNarcoticsOpiate Substitution TreatmentPatient ComplianceRegression AnalysisSelf-Help GroupsSocioeconomic FactorsSubstance Abuse DetectionTreatment OutcomeConceptsMethadone maintenance programEfficacy of disulfiramAlcohol use disorderCocaine useStandard counselingUse disordersCommunity-based methadone maintenance programRandomized placebo-controlled trialPlacebo-controlled trialCurrent alcohol use disorderTwelve-step facilitationCocaine-negative urinesLess cocaine useMethadone maintenanceStep FacilitationCocaine-dependent individualsPlaceboBetter outcomesDisulfiram efficacyTreatment approachesFactorial trialDisulfiramMaintenance programRelative efficacyCocaine usersDeveloping and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation
McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S. Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation. Nicotine & Tobacco Research 2012, 14: 1362-1371. PMID: 22492085, PMCID: PMC3482010, DOI: 10.1093/ntr/nts090.Peer-Reviewed Original ResearchConceptsSubsequent ad libitum smokingSmoking cessation medicationsAd libitum smokingCessation medicationsNicotine deprivationSmoking cessationNovel smoking cessation medicationsRatings of cravingSmoking lapse behaviorHuman laboratory modelSecondary outcomesClinical efficacyClinical findingsFirst cigaretteMedication effectsSmokingMedication developmentCigarette effectsMedicationsLapse behaviorSmoking lapseTranslational toolScreen medicationsMonetary reinforcementTranslational work